Navigation Links
The Medicines Company's Cangrelor - Is it better than Plavix for Acute Coronary Syndrome?
Date:11/26/2013

DUBLIN, Nov. 26, 2013 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/h45rfk/the_medicines) has announced the addition of the "The Medicines Company's Cangrelor - Is it better than Plavix for Acute Coronary Syndrome?" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Cangrelor is a reversible, intravenous inhibitor of the P2Y12 receptor whose effect is to inhibit adenosine diphosphate-induced platelet aggregation. The Medicines Company is developing it for use in the setting of patients undergoing percutaneous coronary intervention procedures (PCI), specifically those who have not used Plavix or other P2Y12 inhibitors in the prior week. Two previous phase III trials failed to meet their primary endpoints. Thus, approval hangs on the results of a third trial, CHAMPION-PHOENIX that should report before year-end. This report explores the probability of a favorable phase III outcome, eventual approval, and the market opportunity.

Key Topics Covered:

INTRODUCTION

1. Acute coronary syndromes (ACS)

2. Thrombosis is at the center of causality

3. Clinicians use several approaches to platelet inhibition


CANGRELOR

1. Phase I/II trials

2. Pivotal trials


CLINICAL AND REGULATORY DISCUSSION

1. Why did CHAMPION-PCI and CHAMPION-PLATFORM fail?

2. Given the PCI and PLATFORM results, what are the lessons for PHOENIX?

3. Are there meaningful safety concerns associated with cangrelor?

4. Are there any bleeding concerns?

5. Possible adverse pulmonary effects of cangrelor

6. What are the regulatory issues that cangrelor will face?

7. Other relevant FDA guidance

8. In summary

MARKET OPPORTUNITY

1. Overview of issues

2. Market estimates

3. Pipeline products

Companies Mentioned

  • Eli Lilly,
  • Bristol Myers Squibb,
  • Astra Zeneca

For more information visit http://www.researchandmarkets.com/research/h45rfk/the_medicines

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Laura Wood , +353-1-481-1716, press@researchandmarkets.net




'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Worlds Only USDA Certified Organic and FDA Registered Homeopathic Medicines Guaranteed to Work
2. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
3. Warning: Not All Cold Sore Medicines Are Created Equal
4. Kick Off Summer Vacation With Five Simple Tips to Safely Store Medicines While Traveling
5. Global pharmaceutical industry calls for broad-based cooperation to fight online sales of counterfeit medicines around the world
6. Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines
7. New Research Reveals Extent of Poor-Quality Antimalarial Medicines in South American Countries
8. Watson Applauds GPhA Study Demonstrating $1 Trillion in Prescription Drug Savings from Generic Medicines
9. Sigma-taus Antimalarial Awarded "Project of the Year" 2011 by Medicines for Malaria Venture
10. National Community Pharmacists Association and Purdue Pharma Urge Americans to Safeguard Rx Medicines This Holiday Season
11. PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):